Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881875 | 0.82 | STK17B (0.46) | RECQLMAPTMTNR1AMTNR1BPOLB | |
| SCHEMBL21327224 | 0.82 | NNMT (0.50) | RECQLMAPTMEN1KMT2APABPC1 | |
| SCHEMBL24853339 | 0.79 | RECQL (0.45) | RECQLMAPTMEN1KMT2APABPC1 | |
| SCHEMBL30184866 | 0.79 | RECQL (0.45) | RECQLMAPTMEN1KMT2APABPC1 | |
| SCHEMBL13361818 | 0.77 | RECQL (0.39) | RECQLMAPTMEN1KMT2APABPC1 | |
| SCHEMBL21327577 | 0.77 | KMT2A (0.40) | RECQLMAPTMEN1KMT2APABPC1 | |
| SCHEMBL4307667 | 0.77 | POLB (0.41) | RECQLMAPTMEN1KMT2APOLB | |
| SCHEMBL13892471 | 0.73 | LOXL2 (0.44) | RECQLMTNR1AMTNR1BNNMTSMN1; SMN2 | |
| SCHEMBL21591699 | 0.71 | MTNR1B (0.51) | RECQLMEN1KMT2APABPC1MTNR1A | |
| SCHEMBL27732222 | 0.71 | GAA (0.38) | RECQLMAPTMEN1KMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| EP-1912945-A1 | N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007016358-A1 | N-(PYRIDIN-4-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | SHBG, AR, NR5A1 | RECQL 2581/4885MAPT 1721/4885MEN1 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.